A New Preclinical and Manufacturing Roadmap Aims to Accelerate Type 1 Diabetes Islet Cell Therapies Towards Human Clinical Trials

A groundbreaking publication by Breakthrough T1D and its collaborators has unveiled the first comprehensive preclinical testing and manufacturing roadmap designed to expedite the progression of islet cell therapies for type 1 diabetes (T1D) into human clinical trials. This pivotal document, published in Stem Cell Reports, addresses a critical bottleneck in the development of these potentially life-changing treatments, offering a clear pathway for researchers and developers seeking to bring innovative T1D therapies to patients more rapidly.

The development of any new therapeutic, particularly those involving complex biological entities like islet cells, necessitates a rigorous scientific validation process before human application. This process, known as preclinical study, involves extensive laboratory research to ascertain the potential efficacy and safety of the therapy. Concurrently, any therapy intended for human trials must undergo meticulous manufacturing validation and quality control to guarantee that each dose administered meets stringent quality standards, ensuring consistency and patient safety. This new publication directly tackles these essential stages, providing a much-needed framework for accelerating the translation of promising islet cell research into tangible clinical benefits for individuals living with T1D.

Understanding the Preclinical and Manufacturing Imperative

Type 1 diabetes is an autoimmune disease characterized by the immune system’s destruction of insulin-producing beta cells in the pancreas. This loss of beta cells leads to an inability to regulate blood glucose levels, necessitating lifelong insulin therapy and posing significant risks of long-term complications, including cardiovascular disease, kidney failure, blindness, and nerve damage. Islet cell transplantation, a form of cell therapy, aims to restore the body’s natural insulin production by transplanting functional islet cells, typically derived from donor pancreases or generated from stem cells in a laboratory setting.

While islet cell therapies have shown immense promise, with some individuals already achieving insulin independence through existing clinical trials, the path from laboratory discovery to widespread clinical availability is often protracted and complex. A significant challenge lies in scaling up the production of these therapeutic cells to meet the demands of larger clinical studies and, eventually, widespread patient access. This scaling process requires not only the ability to produce large quantities of cells but also to ensure that these cells are consistently pure, potent, and safe for administration.

The publication by Breakthrough T1D, spearheaded by Marjana Marinac, Pharm.D., Associate Vice President of Regulatory Affairs, and Chanel Press, Ph.D., Director of Regulatory Affairs, alongside Esther Latres, Ph.D., Senior Vice President of Research, Nicholas Mamrak, Ph.D., Senior Scientist, and a consortium of leading external experts, directly addresses these critical needs. It synthesizes general guidance from regulatory bodies like the U.S. Food and Drug Administration (FDA) and translates it into a specific, actionable roadmap for developers of manufactured islet cell therapies. This roadmap outlines the types of preclinical studies, data requirements, and manufacturing considerations that regulatory agencies expect to see when evaluating applications for first-in-human clinical trials.

A Roadmap for Accelerated Development

The core of the publication lies in its detailed approach to preclinical development and manufacturing. Historically, the lack of a standardized, universally accepted preclinical and manufacturing pathway has contributed to delays in bringing cell therapies to clinical trials. Developers often faced uncertainty regarding the specific types and extent of preclinical testing required, the manufacturing processes that would be deemed acceptable, and the quality control measures necessary to satisfy regulatory scrutiny. This uncertainty could lead to costly and time-consuming iterations of research and development, ultimately prolonging the time it takes for a promising therapy to reach patients.

This new roadmap aims to mitigate such delays by providing clarity and direction. It delineates key areas of focus for preclinical studies, including assessments of cell identity, purity, potency, and safety, as well as efficacy in relevant animal models. Furthermore, it offers guidance on manufacturing processes, emphasizing the importance of Good Manufacturing Practices (GMP), process validation, and robust quality assurance systems. By providing this comprehensive framework, the publication empowers researchers and companies to design their development programs more efficiently, anticipating regulatory requirements from the outset.

The implications of this standardized approach are profound. For T1D patients and their families, it means a potentially faster route to accessing novel therapies that could liberate them from the daily burden of insulin injections and constant glucose monitoring. For the scientific and biotech communities, it represents a significant step forward in streamlining the complex journey of cell therapy development, fostering innovation and encouraging investment in this critical area of medical research.

Project ACT: Driving Cell Therapy Advancement

This publication is a cornerstone of Breakthrough T1D’s broader strategic initiative, Project ACT (Accelerate Cell Therapies). Launched to address the urgent need for scalable and accessible cell therapies for T1D, Project ACT is a multi-faceted program designed to simultaneously advance research, development, regulatory policies, and patient access to these transformative treatments. A key tenet of Project ACT is the pursuit of islet cell therapies that do not require broad immunosuppression, a significant hurdle for current cell transplantation approaches that can lead to serious side effects and long-term health risks.

The development of manufactured islet cell therapies is central to achieving the goals of Project ACT. Unlike therapies derived from donor pancreases, which are limited by organ availability, manufactured cell therapies offer the potential for scalable, consistent, and potentially more accessible treatment options. By providing a clear preclinical and manufacturing roadmap, Breakthrough T1D is actively working to de-risk and accelerate the development of these manufactured cell therapies, aligning with its mission to bring curative solutions to T1D patients as quickly as possible.

The organization’s commitment to this endeavor is underscored by the expertise and collaborative spirit embedded within the publication. The involvement of its own regulatory affairs and research teams, coupled with the contributions of leading external collaborators, signifies a robust and well-informed approach to tackling a complex scientific and regulatory challenge.

Dissemination and Future Collaborations

The impact of this foundational work is poised to extend beyond the publication itself, with active plans for its dissemination and integration into the broader scientific community. The findings will be formally presented as a poster at the prestigious International Society for Stem Cell Research (ISSCR) 2026 Annual Meeting in Montreal, Canada. This platform will provide an invaluable opportunity for direct engagement with researchers, clinicians, and industry stakeholders, fostering discussions and collaborations aimed at translating the roadmap into practical application. Attendees are encouraged to visit the poster during Poster Session 2 on Thursday, July 9, 2026, from 4:00 to 5:15 p.m.

Further solidifying its commitment to collaborative advancement, Breakthrough T1D, in conjunction with the National Institute of Diabetes and Digestive Diseases (NIDDK), is co-hosting a critical workshop in September. This workshop will convene leaders from academia, industry, government agencies, and patient advocacy groups to delve deeper into the multifaceted challenges and strategic approaches surrounding islet cell therapies. A significant focus will be placed on manufacturing innovations and nonclinical considerations, building upon the framework established by the new publication. This initiative exemplifies a holistic approach to problem-solving, bringing together diverse perspectives to accelerate progress in the field. Information and registration details for the workshop are available through the NIDDK website, highlighting the collaborative nature of this critical endeavor.

The Broader Impact on T1D Treatment Landscape

The implications of this published roadmap extend far beyond the immediate acceleration of preclinical studies. By providing a clear, standardized pathway, it is anticipated to:

• Stimulate Investment and Innovation: A well-defined regulatory pathway reduces the perceived risk for investors, potentially leading to increased funding for companies and academic institutions developing T1D cell therapies. This, in turn, can foster greater innovation and a broader range of therapeutic approaches.
• Facilitate Regulatory Approval: With a clear understanding of the data and manufacturing requirements, developers can better prepare their submissions to regulatory agencies, potentially leading to more efficient and predictable approval processes for new therapies.
• Enhance Collaboration: The roadmap can serve as a common language and framework for collaboration among researchers, manufacturers, and regulatory bodies, fostering a more cohesive and efficient ecosystem for cell therapy development.
• Improve Patient Access: Ultimately, the successful translation of promising cell therapies into approved treatments will lead to greater accessibility for individuals with T1D, offering them improved quality of life and the potential for long-term remission from the disease.

The journey towards a functional cure for type 1 diabetes is complex and requires sustained effort across multiple fronts. This new publication from Breakthrough T1D represents a significant stride forward, offering a tangible and actionable plan to overcome critical developmental hurdles. By providing a clear roadmap for preclinical testing and manufacturing, it lays the groundwork for a faster, more efficient path to bringing life-changing islet cell therapies from the laboratory bench to the patient bedside, embodying the spirit of Project ACT and the ongoing quest to accelerate cell therapies for all those affected by T1D.